Table 1.
Study details and findings
| Author and Year | Country | Study Type, Sample Size | Intervention | Outcomes | Between-group Improvements at Follow-up | |
|---|---|---|---|---|---|---|
| Intervention Group | Control Group | |||||
| Guney et al.2016 | Turkey |
RCT N = 54 |
Microfracure surgery + PRP |
Group 2 (N = 19): Microfracure surgery Group 3 (N = 13): Mosaicplasty |
VAS Pain: Improved (P < 0.001) AOFAS: Improved (P < 0.001) FAAM: Absent baseline data; no intergroup differences at endpoint |
No differences between groups at last follow-up; Median 42 months (range: 12–84). |
| Guney et al.2015 | Turkey |
Controlled trial N = 35 |
Microfracure surgery + PRP | Group 2 (N = 16): Microfracure surgery |
VAS Pain: Improved (P < 0.001) AOFAS: Improved (P < 0.001) FAAM: Improved (P = 0.001) |
Significantly improved at last follow-up as compared to control. Follow-up average of 16.2 months (Range: 12–24) |
| Görmeli et al.2015 | Turkey |
RCT N = 40 |
PRP injection |
Group 2 (N = 14): Hyaluronic acid injection Group 3 (N = 13): Saline injection |
VAS pain: Improved (P < 0.05) AOFAS: Improved (P < 0.05) Patient Satisfaction: 61.5% satisfied Adverse Events: None reported |
Significantly improved as compared to control, improved patient satisfaction at 1 year. Follow-up average of 15.3 months (range: 11–25). |
| Paget et al.2021 | Netherlands |
RCT N = 100 |
PRP injection | Group 2 (N = 52): Saline injection |
AOFAS: Improved (P < 0.001) Adverse Events: 1 serious case reported but deemed unrelated to intervention. 13 other adverse events in the PRP group and 8 in the placebo group. |
No differences between groups over 26 weeks; |
| Sampson S et al. 2016 | USA |
Case Series N = 125 (ankle, N = 6) |
Bone marrow concentrate + PRP | No control |
VAS pain: Improved Patient Satisfaction: median 9.0/10.0 |
Follow-up mean 148 days, minimum 56 days. |
| Fukawa et al. 2017 | Japan |
Case Series N = 20 |
PRP injection | No control |
VAS pain: Improved (P < 0.05) JSSF Ankle/Hindfoot Scale: Improved (P < 0.05) SAFE-Q: Improved (P < 0.05) Adverse Events: 1 patient had mild pain and swelling resolved within 2 days |
Significantly improved VAS and JSSF scores at 4, 12, and 24 weeks. Significantly improved SAFE-Q at 12 weeks. |
| Li et al. 2021 | China |
Cohort N = 106 |
Joint distraction osteogenesis + PRP injection | Group 2 (N = 53): Surgical group | The total effective rate was 98.11% in the combined group and 77.36% in the operation group. |
Significant better overall curative effect in PRP group. No significant difference in the incidence of ARs (P > 0.05). |
| Repetto et al. 2017 | Italy |
Case Series N = 20 |
PRP injection | No control |
VAS pain: Improved (P < 0.05) FADI: Improved (P < 0.05) Patient Satisfaction: 80% satisfied Adverse Events: None reported |
Significantly improved VAS and FADI at mean 17.7 month follow-up (range: 12–30) |
| Akpancar et al. 2019 | Turkey |
Cohort N = 49 |
PRP injection | Group 2 (N = 27): Prolotherapy injection |
AOFAS: Improved (P < 0.001) AOS: Improved (P < 0.001) |
No significant difference between groups at 1 year follow-up. |
| Mei-Dan et al. 2012 | Israel |
RCT N = 30 |
PRP injection | Group 2 (N = 15): Hyaluronic acid injection |
AHFS :Improved (P < 0.001) VAS pain: Improved (P < 0.001) |
Significantly improved AHFS at mean 28 weeks follow-up. No between group difference inVAS pain. |
RCT: Randomized Controlled Clinical Trial. VAS: Visual Analog Scale. FAAM: Foot and Ankle Ability Measure. AOFAS: American Orthopaedic Foot and Ankle Society scoring system. JSSF: Japanese Society for Surgery of the Foot. SAFE-Q: Self-Administered Foot Evaluation Questionnaire. FADI: Foot and Ankle Disability Index. AOS: Ankle Osteoarthritis Scale. AHFS, Ankle-Hindfoot Scale. Ars: Adverse Reactions.